Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
July 05 2022 - 4:01PM
Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the
“Company”), the developer of the innovative alpha-radiation cancer
therapy Alpha DaRT™, announced today that it will host a hybrid
in-person/virtual key opinion leader (KOL) meeting at Convene
(North Hub Room), located at 530 5th Ave. New York, NY on Monday,
July 18, 2022 beginning at 10:30 am Eastern Time. For those
attending in-person, breakfast will begin at 10:30 am Eastern Time.
For those attending virtually, the presentations and webcast will
begin at 11:00 am Eastern Time.
The meeting will feature presentations from KOLs Michael J.
Zelefsky, MD, Memorial Sloan Kettering Cancer Center, Mark
D’Andrea, MD, University Cancer Centers, and Robert Den, MD, Alpha
Tau's Chief Medical Officer, who will discuss Alpha Tau’s therapy
(the Alpha DaRT radiation technology) and the Company’s clinical
trial outlook. For those attending the event in person, a selection
of the Company’s proprietary applicators will also be available for
demonstration.
The Alpha DaRT technology is based on inserting directly into
the tumor small amounts of radioactive radium-224 affixed to metal
sources which are designed to decay and release radioactive atoms
that diffuse inside the tumor, emitting short-range alpha radiation
that aims to damage and kill cancer cells within a short period of
time.
During the KOL presentations, Alpha Tau’s recent clinical
trials, upcoming U.S. pivotal trial in recurrent cutaneous Squamous
Cell Carcinoma (SCC), other upcoming clinical trials, and the
Company’s pre-clinical work on potential immunological effects of
the Alpha DaRT technology will be discussed.
A Q&A session will follow the formal presentations. To
register for the event or webcast, please click here. If you would
like to attend in person, please indicate this selection when
registering and you will receive an email confirming your
attendance closer to the event with specific location details.
Michael J. Zelefsky, MD is an internationally renowned radiation
oncologist who is Professor of Radiation Oncology at Memorial Sloan
Kettering Cancer Center and the Weil Cornell Medical Center. He
serves as the Chief of the Brachytherapy Service at MSKCC which
represents one of the most active sites for performing
brachytherapy in the world, involved in highly innovative and
sophisticated oncology procedures incorporating the delivery of
radiation-based implants directly into tumors. Dr. Zelefsky is the
incumbent Greenberg Chair of Prostate Cancer Research at MSKCC and
serves as the Co-Leader of the Genitourinary Disease Management
team for the hospital as well as the Director of GU Radiation
Oncology. He has published over 400 papers in Oncology as well as
Book Chapters and Reviews. He also serves as the Editor in Chief of
the Journal Brachytherapy.
Mark D’Andrea, MD is a board-certified Radiation Oncologist
providing services in Houston, Brenham, and Huntsville. Primarily
affiliated with University Cancer Centers, Dr. D’Andrea has been
named one of Houston’s Top Doctors from 2016 through 2021. He has
received the Patient’s Choice award, Most Compassionate Doctor, and
Peer Reviewed Physician, among several other distinctions over the
years. Dr. D’Andrea has over 30 years of expertise in breast
cancer, prostate cancer, lung cancer, head and neck cancer,
gastrointestinal cancer, and gynecologic cancer treatments. Dr.
D'Andrea has been published in over 30 clinical medical research
publications.
Robert Den, MD has served as Alpha Tau’s Chief Medical Officer
since 2019. Dr. Den specializes in radiation oncology and conducts
innovative research across a broad variety of malignancies. From
2011 to 2015 and from 2015 to the present, Dr. Den has served as an
assistant professor and an associate professor, respectively, at
Jefferson University, where he has also served as a clinical
practitioner since 2007. Dr. Den holds a B.S. in Chemistry from
Yale University and an M.D. from Harvard Medical School.
About Alpha DaRTAlpha DaRT (Diffusing
Alpha-emitters Radiation Therapy) is designed to enable highly
potent and conformal alpha-irradiation of solid tumors by
intratumoral delivery of radium-224 impregnated sources. When the
radium decays, its short-lived daughters are released from the
sources and disperse while emitting high-energy alpha particles
with the goal of destroying the tumor. Since the alpha-emitting
atoms diffuse only a short distance, Alpha DaRT aims to mainly
affect the tumor, and to spare the healthy tissue around it.
About Alpha Tau Medical Ltd.Founded in 2016,
Alpha Tau is an Israeli medical device company that focuses on
research, development, and potential commercialization of the Alpha
DaRT for the treatment of solid tumors. The technology was
initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari
from Tel Aviv University.
Forward-Looking StatementsThis press release
includes "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. When used herein,
words including "anticipate," "being," "will," "plan," "may,"
"continue," and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Alpha Tau's current expectations and various
assumptions. Alpha Tau believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain. Alpha
Tau may not realize its expectations, and its beliefs may not prove
correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various important factors, including, without limitation: (i)
Alpha Tau's ability to receive regulatory approval for its Alpha
DaRT technology or any future products or product candidates; (ii)
Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence
of significant losses to date; (iv) Alpha Tau's need for additional
funding and ability to raise capital when needed; (v) Alpha Tau's
limited experience in medical device discovery and development;
(vi) Alpha Tau's dependence on the success and commercialization of
the Alpha DaRT technology; (vii) the failure of preliminary data
from Alpha Tau's clinical studies to predict final study results;
(viii) failure of Alpha Tau's early clinical studies or preclinical
studies to predict future clinical studies; (ix) Alpha Tau's
ability to enroll patients in its clinical trials; (x) undesirable
side effects caused by Alpha Tau's Alpha DaRT technology or any
future products or product candidates; (xi) Alpha Tau's exposure to
patent infringement lawsuits; (xii) Alpha Tau's ability to comply
with the extensive regulations applicable to it; (xiii) the ability
to meet Nasdaq's listing standards; (xiv) costs related to being a
public company; (xv) changes in applicable laws or regulations;
(xix) impacts from the COVID-19 pandemic; and the other important
factors discussed under the caption "Risk Factors" in Alpha Tau's
annual report filed on form 20-F with the SEC on March 28, 2022,
and other filings that Alpha Tau may make with the United States
Securities and Exchange Commission. These and other important
factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While Alpha Tau may
elect to update such forward-looking statements at some point in
the future, except as required by law, it disclaims any obligation
to do so, even if subsequent events cause its views to change.
These forward-looking statements should not be relied upon as
representing Alpha Tau's views as of any date subsequent to the
date of this press release.
Investor Relations ContactIR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024